Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be 18 years old or older
- You must have been diagnosed with a specific type of kidney cancer called "clear cell renal cell carcinoma," confirmed by a tissue or cell sample test
- Your cancer must have spread to other parts of the body, as shown by a scan or biopsy of the affected area
- You must not have received any previous treatment for your kidney cancer
- Your doctors must have recommended a first-line treatment combining certain types of cancer medicines (immunotherapy plus a targeted therapy, or two immunotherapy medicines together), as used at the University Hospital of Bologna
- You must have already had a specific type of full-body CT scan (called a dual-energy spectral CT) within 4 weeks before starting treatment
- A preserved tissue sample from your diagnosis (stored in a special way called "formalin-fixed, paraffin-embedded") must be available and must have been stored for less than 15 years, so that certain genetic tests can be carried out
- You must be willing to take part in the study and have signed a consent form after being fully informed about it
Who may not be able to join:
- There are no listed exclusion criteria for this trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Francesco Massari, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phone: 0511242204
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Response to first-line drug therapy (with immuno-combinations) in patients with metastatic renal cell carcinoma
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.